← Search & browse all drugs
RESPIRATORY SYSTEM › NASAL PREPARATIONS › NASAL DECONGESTANTS FOR SYSTEMIC USE › Sympathomimetics
phenylpropanolamine, combinations
R01BA51
Forms & Strengths
- Oral tablet 10 mg, 12.5 mg, 25 mg
- Oral syrup 2 mg/mL
- Combination tablets with antihistamine (e.g., 10 mg PPA + 2 mg chlorpheniramine)
Adult Dosing
- 10–25 mg PO q4‑6 h as needed; max 100 mg/24 h
- In combination products follow labeled total PPA dose, do not exceed 100 mg/24 h
Pediatric Dosing
- ≤12 yr: generally not recommended; if used, 5 mg PO q6‑8 h, max 30 mg/24 h
- Infants & children <2 yr: contraindicated
Indications
- Temporary relief of nasal congestion due to common cold, allergic rhinitis, sinusitis
- Used in multi‑symptom cold formulations for decongestion
Mechanism of Action
- Indirect sympathomimetic; releases norepinephrine from nerve terminals
- Activates peripheral α‑adrenergic receptors → nasal mucosal vasoconstriction
Contraindications
- Severe hypertension or uncontrolled cardiovascular disease
- Coronary artery disease, angina, arrhythmias
- Hyperthyroidism, pheochromocytoma
- Glaucoma (narrow‑angle)
- MAO‑inhibitor therapy
- Pregnancy (especially 1st trimester) and lactation
- Known hypersensitivity to phenylpropanolamine
Adverse Reactions
- Tachycardia, palpitations
- Elevated blood pressure, headache
- Nervousness, insomnia, restlessness
- Dizziness, vertigo
- Nausea, abdominal discomfort
- Urinary retention (especially in men)
- Rare: hemorrhagic stroke, myocardial ischemia
Drug Interactions
- MAO inhibitors – risk of hypertensive crisis
- Other sympathomimetics (e.g., ephedrine, phenylephrine) – additive pressor effects
- Tricyclic antidepressants, SSRIs – may increase catecholamine levels
- Beta‑blockers – may blunt tachycardia but increase hypertension risk
- Antihypertensives – reduced efficacy
- Antihistamines – may enhance sedation in some combos
- Caffeine – additive CNS stimulation
Curated Content: Needs Vetting Before Put to Clinical Use